Momenta Pharmaceutical (MNTA -5.7%) takes a hit after UBS downgraded the shares to Neutral...


Momenta Pharmaceutical (MNTA -5.7%) takes a hit after UBS downgraded the shares to Neutral earlier this morning, citing limited near-term catalysts and cash burn following the recent negative court ruling in the Copaxone case. The firm retains its price target of $15.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs